<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
08.05.2018 22:15:00

Versartis Reports First Quarter 2018 Financial Results

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018."We have undertaken additional efforts to aggressively manage our cash as we work diligently to complete our strategic review process," said Jay Shepard, President and CEO of Versartis, Inc.  "We acknowledge the patience our shareholders have shown during this process and we are committed to providing an update as soon as we can."First Quarter 2018 Financial ResultsFor the first quarter ended March 31, 2018, Versartis reported a net loss of approximately $9.0 million, or $0.25 per share, basic and diluted, compared to a net loss for the first quarter ended March 31, 2017 of $29.7 million, or $0.85 per share, basic and diluted.Total operating expenses for the quarter ended March 31, 2018 were $8.5 million compared to $29.7 million for the quarter ended March 31, 2017. Research and development (R&D) expenses for the quarter ended March 31, 2018 were $3.6 million, compared to $22.0 million for the quarter ended March 31, 2017. The decrease in R&D expenses was primarily due to the termination of clinical and manufacturing related contracts that supported the company's Phase 3 clinical trials for somavaratan following the Phase 3 VELOCITY trial failing to meet its primary endpoint. General and administrative (G&A) expenses were $4.9 million for the quarter ended March 31, 2018 compared to $7.7 million for the quarter ended March 31, 2017.  The decrease in G&A expenses was primarily due to the reduction in workforce and our continued efforts to reduce consulting and professional services expenses following the Phase 3 VELOCITY trial failing to meet its primary endpoint.  Total operating expenses for the quarter ended March ...Full story available on Benzinga.com
Weiter zum vollständigen Artikel bei "Benzinga"

Analysen zu Versartis Incmehr Analysen

02.03.18 Versartis Hold Canaccord Adams
22.09.17 Versartis Equal weight Barclays Capital

Eintrag hinzufügen

Proteste in Hongkong: Mögliche Folgen für die Aktienmärkte

Finanzen.net News